PURPOSE: We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. PATIENTS AND METHODS: ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to determine the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics. Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics. A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size. RESULTS: Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies. ABT-888 demonstrated good oral bioavailability and was well tolerated. Statistically significant inhibition of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels. CONCLUSION: Within 5 months of study activation, we obtained pivotal biochemical and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents. In addition to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology.
PURPOSE: We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. PATIENTS AND METHODS: ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to determine the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics. Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics. A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size. RESULTS: Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies. ABT-888 demonstrated good oral bioavailability and was well tolerated. Statistically significant inhibition of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels. CONCLUSION: Within 5 months of study activation, we obtained pivotal biochemical and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents. In addition to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology.
Authors: M Shiobara; M Miyazaki; H Ito; A Togawa; N Nakajima; F Nomura; N Morinaga; M Noda Journal: J Gastroenterol Hepatol Date: 2001-03 Impact factor: 4.029
Authors: Cherrie K Donawho; Yan Luo; Yanping Luo; Thomas D Penning; Joy L Bauch; Jennifer J Bouska; Velitchka D Bontcheva-Diaz; Bryan F Cox; Theodore L DeWeese; Larry E Dillehay; Debra C Ferguson; Nayereh S Ghoreishi-Haack; David R Grimm; Ran Guan; Edward K Han; Rhonda R Holley-Shanks; Boris Hristov; Kenneth B Idler; Ken Jarvis; Eric F Johnson; Lawrence R Kleinberg; Vered Klinghofer; Loren M Lasko; Xuesong Liu; Kennan C Marsh; Thomas P McGonigal; Jonathan A Meulbroek; Amanda M Olson; Joann P Palma; Luis E Rodriguez; Yan Shi; Jason A Stavropoulos; Alan C Tsurutani; Gui-Dong Zhu; Saul H Rosenberg; Vincent L Giranda; David J Frost Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Robert Kinders; Ralph E Parchment; Jay Ji; Shivaani Kummar; Anthony J Murgo; Martin Gutierrez; Jerry Collins; Larry Rubinstein; Oxana Pickeral; Seth M Steinberg; Sherry Yang; Melinda Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Mel Simpson; Joseph E Tomaszewski; James H Doroshow Journal: Mol Interv Date: 2007-12
Authors: Anthony J Murgo; Shivaani Kummar; Larry Rubinstein; Martin Gutierrez; Jerry Collins; Robert Kinders; Ralph E Parchment; Jiuping Ji; Seth M Steinberg; Sherry X Yang; Melinda Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James H Doroshow Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: Ronald Stoller; John C Schmitz; Fei Ding; Shannon Puhalla; Chandra P Belani; Leonard Appleman; Yan Lin; Yixing Jiang; Salah Almokadem; Daniel Petro; Julianne Holleran; Brian F Kiesel; R Ken Czambel; Benedito A Carneiro; Emmanuel Kontopodis; Pamela A Hershberger; Madani Rachid; Alice Chen; Edward Chu; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2017-08-02 Impact factor: 3.333
Authors: Robert J Kinders; Melinda Hollingshead; Scott Lawrence; Jiuping Ji; Brian Tabb; William M Bonner; Yves Pommier; Larry Rubinstein; Yvonne A Evrard; Ralph E Parchment; Joseph Tomaszewski; James H Doroshow Journal: Clin Cancer Res Date: 2010-10-05 Impact factor: 12.531
Authors: Shivaani Kummar; Jiuping Ji; Robert Morgan; Heinz-Josef Lenz; Shannon L Puhalla; Chandra P Belani; David R Gandara; Deborah Allen; Brian Kiesel; Jan H Beumer; Edward M Newman; Larry Rubinstein; Alice Chen; Yiping Zhang; Lihua Wang; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow Journal: Clin Cancer Res Date: 2012-02-03 Impact factor: 12.531
Authors: Bastiaan Evers; Eva Schut; Eline van der Burg; Tanya M Braumuller; David A Egan; Henne Holstege; Pauline Edser; David J Adams; Richard Wade-Martins; Peter Bouwman; Jos Jonkers Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531